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Brain-derived neurotrophic factor (BDNF) modulates
glutamatergic excitatory transmission in hippocampal
primary cultures by acting at a presynaptic locus.
Although it has been suggested that BDNF also modu-
lates adult hippocampus glutamatergic transmission,
this remains a matter of controversy. To clarify a puta-
tive role for this neurotrophin in the modulation of gluta-
mate release we applied exogenous BDNF to isolated
adult rat hippocampal nerve terminals. BDNF, at 100
ng/ml, potentiated by 25% the Kþ-evoked release of
[3H]glutamate from hippocampal synaptosomes. The
small effect of BDNF on [3H]glutamate release corre-
lated with a modest increase in phospholipase Cg
(PLCg) phosphorylation, and with the lack of effect of
BDNF on extracellular-signal regulated kinase (ERK)
and Akt phosphorylation. Immunocytochemistry studies
demonstrated that only about one-third of glutamater-
gic synaptosomes were positive for TrkB immunoreac-
tivity. Furthermore, biotinylation and subsynaptic frac-
tionation studies showed that only one-fourth of total
full-length TrkB was present at the plasma membrane,
evenly distributed between the presynaptic active zone
and the postsynaptic density. These results indicate
that BDNF modulates synaptic transmission presynapti-
cally in a small subset of hippocampal glutamatergic
synapses that contain TrkB and that express the recep-
tor on the plasma membrane. VC 2006 Wiley-Liss, Inc.
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Neurotrophins are recognized currently as impor-
tant modulators of synaptic plasticity in central and pe-
ripheral nervous systems in addition to their role in neu-
ronal differentiation and survival (Schuman, 1999; Poo,
2001). Particular attention has been given to the hippo-
campus because it is a prominent site of expression of
BDNF and NT-3 and their receptors (Ernfors et al.,
1990; Klein et al., 1990; Lamballe et al., 1991). The
physiological actions of BDNF, a well established modu-
lator of hippocampal synaptic transmission, are mediated
by the high-affinity receptor tyrosine kinase TrkB, and
the low affinity pan-neurotrophin receptor p75 (Chao,
2003). BDNF binding to TrkB leads to the activation of
the ERK, the phosphatidylinositol 3-kinase (PI3-K) and
the PLCg pathways, which transduce most of the cellu-
lar responses to BDNF (Huang and Reichardt, 2003).
Studies in hippocampal primary cultures show that
exogenously applied BDNF enhances the evoked and
spontaneous excitatory synaptic transmission (Lessmann
et al., 1994; Levine et al., 1995). Although a postsynaptic
contribution to this effect has been suggested (Levine
et al., 1995, 1998), a predominant presynaptic action has
been demonstrated convincingly in cultured hippocampal
neurons (Lessmann and Heumann, 1998; Li et al.,
1998a,b; Berninger et al., 1999; Schinder et al., 2000). A
recent study showed that early presynaptic and late postsyn-
aptic components contribute independently to BDNF-
induced synaptic plasticity in dissociated cultures of hippo-
campal neurons (Alder et al., 2005).
In contrast, in hippocampal preparations from
mature animals, the effect of BDNF on excitatory synaptic
transmission remains a matter of controversy. An early
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study using acutely dissociated hippocampal slices showed
that superfusion with BDNF induces a long lasting poten-
tiation of excitatory synaptic transmission in the CA1 area,
acting at a presynaptic locus (Kang and Schuman, 1995).
Other groups have been unable to reproduce these results
(Figurov et al., 1996; Patterson et al., 1996; Tanaka et al.,
1997; Frerking et al., 1998; Gottschalk et al., 1998). It has
been suggested that low penetration of BDNF into the
slice tissue due to different rates of neurotrophin applica-
tion is the underlying reason for this discrepancy (Kang
et al., 1996). Nonetheless, superfusion rates cannot solely
account for such inconsistencies because a lack of BDNF
effect was also observed in studies using rapid superfusion
rates (Tanaka et al., 1997; Frerking et al., 1998). A lasting
enhancement of synaptic transmission by BDNF in the
dentate gyrus ‘‘in vivo’’ was also reported (Messaoudi
et al., 1998), but this was demonstrated to occur, at least
partially, through postsynaptic mechanisms (Messaoudi
et al., 2002; Ying et al., 2002). Accordingly, stimulation of
dentate gyrus synaptosomes with BDNF did not affect
KCl-evoked glutamate release. In this study, however, a
synergistic effect was observed between the neurotrophin
and (1S,3R)ACPD [(1S,3R)-1-aminocyclopentane-1,3-
dicarboxylic acid], a metabotropic glutamate receptor ago-
nist, in the potentiation of depolarization-evoked gluta-
mate release (Gooney and Lynch, 2001).
BDNF has been implicated more convincingly in
hippocampal long-term potentiation (LTP). BDNF knock-
out mice show severe impairments in LTP in the CA1
region that can be rescued by application of exogenous
BDNF or by virus-mediated BDNF gene transfer (Korte
et al., 1996; Patterson et al., 1996). Scavenging of endoge-
nous BDNF or genetically engineered reduction of TrkB
levels also leads to deficits in hippocampal LTP (Figurov
et al., 1996; Minichiello et al., 1999; Xu et al., 2000). It has
been suggested that BDNF plays a permissive role in this
event by maintaining an appropriate number of docked
vesicles at the active zone, thus preventing synaptic fatigue
(Figurov et al., 1996; Pozzo-Miller et al., 1999; Tartaglia
et al., 2001) . An instructive role for BDNF in LTP induc-
tion has also been supported by recent reports (Kossel et al.,
2001), and is consistent with BDNF expression and release
in response to activity in the hippocampus (Patterson et al.,
1992; Goodman et al., 1996; Hartmann et al., 2001).
Due to the existing controversy on whether BDNF
acts presynaptically to modulate excitatory synaptic trans-
mission in the adult hippocampus, we used purified
nerve terminals obtained from adult rats to directly test if
this neurotrophin modulated the evoked release of gluta-
mate. In parallel, we also monitored if BDNF activated




Fatty acid free bovine serum albumin (BSA) and K-252a
were obtained from Calbiochem-Novabiochem Intl. (La Jolla,
CA). Reagents used in immunoblotting experiments were
purchased from Bio-Rad (Hercules, CA). [3H]Glutamate (spe-
cific activity, 45 Ci/mmol), polyvinylidene difluoride (PVDF)
membranes, alkaline phosphatase-linked secondary antibodies,
enhanced chemifluorescence (ECF) reagent, and Percoll were
obtained from Amersham Biosciences (Buckinghamshire, Eng-
land). The rabbit polyclonal antibody against dually phospho-
rylated ERK was purchased from Promega (Madison, WI).
The mouse anti-TrkB antibody was from BD Biosciences
Europe (Erembodegem, Belgium), rabbit anti-TrkB was from
Santa Cruz Biotechnology (Santa Cruz, CA), and mouse anti-
Trk (E7) was from Zymed (Carlsbad, CA). The rabbit anti-
phospho-Akt (Ser 473), anti-phospho-PLCg (Tyr 783), and
anti-phospho-Trk (Tyr 490) antibodies were from Cell Signal-
ing Technology (Beverly, MA). Anti-VGluT1 and anti-
VGluT2 guinea pig antibodies were obtained from Chemicon
(Temecula, CA). Rabbit anti-syntaxin 1A was a gift by Dr.
Juan Blasi (Universitat de Barcelona, Barcelona, Spain). The
Alexa Fluor secondary antibodies and the Prolong Antifade
mounting medium were purchased from Molecular Probes
Europe BV (Leiden, The Netherlands). EZ-link sulfo-NHS-
SS-biotin and UltraLink Plus immobilized streptavidin were
obtained from Pierce (Rockford, IL). The Microcon YM-3
centrifugal filter device, used to concentrate protein samples,
was from Millipore Corporation, (Bedford, MA). BDNF was
granted by Regeneron Pharmaceuticals Inc. (Tarrytown, NY).
All other reagents were from Sigma Chemical Co. (St. Louis,
MO) or from Merck KGaA (Darmstadt, Germany).
Isolation of Crude (P2) and Purified Hippocampal
Synaptosomal Fractions
The crude synaptosomal P2 fraction from male Wistar rat
hippocampi was isolated as described elsewhere (McMahon
et al., 1992; Pereira et al., 2002). Briefly, hippocampi of 6- to
8-week-old animals were dissected and homogenized (5%, w/v)
in 0.32 M sucrose, 10 mM HEPES, pH 7.4 (sucrose buffer),
using a Thomas B homogenizer. The suspension was centri-
fuged at 3,000 3 gmax for 2 min, and the supernatants were
spun at 14,600 3 gmax, for 12 min. The upper white layer of
the pellet (P2) was removed and resuspended in sucrose buffer.
Alternatively, a purified hippocampal synaptosomal suspension
was isolated using the Percoll method described elsewhere
(Dunkley et al., 1986) with some modifications (Pereira et al.,
2002). The whole P2 pellet was resuspended in sucrose buffer
and layered on top of Percoll discontinuous gradients (23%,
10%, and 3% Percoll in sucrose buffer for immunoblots and
biotinylation experiments, or in 0.32 M sucrose, 1 mM EDTA,
and 0.25 mM dl-dithiothreitol for immunocytochemistry). After
centrifugation at 36,500 3 gmax, for 5 min (or 25,000 3 gav for
11 min, for immunocytochemistry experiments) the purified
synaptosomal fraction was removed (23%/10% Percoll interface)
and resuspended in 15 vol of sucrose buffer or HEPES buffer
(in mM, 140 NaCl, 5 KCl, 5 NaHCO3, 1.2 NaH2PO4, 1.2
MgCl2, 10 glucose, 10 HEPES, pH 7.4; for immunocytochem-
istry). Percoll was removed by spinning twice at 30,500 3 gmax,
for 20 min (or once at 20,000 3 gav, for 11 min, in the case of
the immunocytochemistry experiments). The alternative protocol
used for the immunocytochemistry experiments allowed us to
obtain purified synaptosomes less contaminated with postsynaptic
structures. The whole procedure was carried out at 0–48C.
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Hippocampal Cell Culture
Hippocampal primary neurons were isolated and main-
tained as described previously (Almeida et al., 2005). Briefly,
hippocampi from E18-E19 Wistar rat embryos were dissected
in Ca2þ- and Mg2þ-free Hank’s balanced salt solution (HBSS;
in mM, 137 NaCl, 5.36 KCl, 4.16 NaHCO3, 0.44 KH2PO4,
0.34 Na2HPO4  2H2O, 5 glucose, supplemented with 1 mM
sodium pyruvate, 10 mM HEPES, and 0.001% phenol red,
pH 7.4), and incubated with 0.9 mg/ml trypsin, for 15 min at
378C, in HBSS containing 0.5 mg/ml deoxyribonuclease I.
Cells were washed in HBSS with 10% fetal bovine serum
(FBS) and mechanically dissociated with a pipette in HBSS.
Hippocampal neurons were maintained in serum-free Neuro-
basal medium supplemented with B27 supplement, 0.5 mM
glutamine, 0.12 mg/ml gentamycin, and 25 lM glutamate, at
a density of 90 3 103 cells/cm2, and kept for 7–8 days at
378C in a humidified incubator with 5% CO2/95% air.
[3H]Glutamate Release
The release of [3H]glutamate was carried out as
described previously (Rodrigues et al., 2005). In short, P2 syn-
aptosomes were washed once with KHR medium (composed
of the following [in mM]: 140 NaCl, 1 EDTA, 5 KCl, 5 glu-
cose, and 10 HEPES, pH 7.4), and resuspended in a Naþ-salt
solution (containing [in mM]: 124 NaCl, 3 KCl, 1.25
NaH2PO4, 25 NaHCO3, 2 MgSO4, 2 CaCl2, and 10 glucose,
pH 7.4), which was gassed with a 95% O2 and 5% CO2 mix-
ture. The nerve terminals were equilibrated at 378C for
10 min, loaded with 0.2 lM [3H]glutamate for 5 min at
378C, washed, layered over Whatman GF/C filters, and
superfused (flow rate, 0.8 ml/min) with Naþ-salt solution for
20 min before starting collection of the superfusate. The syn-
aptosomes were stimulated with 20 mM KCl (isomolar substi-
tution of NaCl by KCl in the salt solution) for 30 sec, at 3
and 9 min after starting sample collection (S1 and S2), trigger-
ing a release of tritium in a Ca2þ-dependent manner that is
mostly glutamate (Lopes et al., 2002). When the effect of
BDNF was tested the neurotrophin was added 2 min before
S2 onward, and its effect was quantified by the modification
of the S2/S1 ratio versus control (i.e., absence of BDNF).
Immunoblotting
Purified synaptosomes (2 mg protein/ml) were pre-incu-
bated for 40 min at 378C in incubation medium, followed by
incubation in reaction medium at 378C for 5 min (control).
BDNF was added for 1, 4, or 30 min. The reaction was stopped
by adding 23 sample buffer (100 mM Tris, 100 mM glycine, 4%
sodium dodecyl sulfate [SDS], 8% b-mercaptoethanol, 8 M urea,
3 mM sodium orthovanadate, and 0.001% bromophenol blue),
and heating the samples for 5 min at 958C. Hippocampal neu-
rons in culture were stimulated for 15 or 30 min with BDNF
before ending the reaction by washing in ice-cold PBS/Ca2þ/
Mg2þ (phosphate-buffered saline with 1 mM CaCl2 and 0.5 mM
MgCl2) and lysing the cells with supplemented RIPA buffer
(150 mM NaCl, 50 mM Tris, 5 mM EGTA, 1% Triton, 0.5%
deoxycholic acid [DOC], 0.1% SDS, pH 7.5, supplemented with
proteinase inhibitors [1 lg/ml chymostatin, leupeptin, antipain,
and pepstatin, CLAP, and 100 lM PMSF] and 1 mM dithiothre-
itol [DTT]). After one freeze-thaw cycle, lysates were centri-
fuged at 16,100 3 gmax during 10 min at 48C, to remove solid
debris, and denatured for 5 min at 958C in 23 sample buffer
(125 mM Tris, 100 mM glycine, 4% SDS, 200 mM DTT, 20%
glycerol, 3 mM sodium orthovanadate. and 0.001% bromophe-
nol blue). Equal amounts of protein (10–30 lg), as determined
by the bicinchoninic acid (BCA) method (Smith et al., 1985),
were separated by electrophoresis on 6 or 10% SDS-polyacryl-
amide gels (SDS-PAGE), and transferred electrophoretically to
polyvinylidene difluoride (PVDF) membranes. These were
blocked for 1 hr at room temperature, in Tris-buffered saline
(137 mM NaCl, 20 mM Tris-HCl, pH 7.6) containing 0.1%
Tween 20 (TBS-T) and 5% low fat milk. Incubation with the
primary antibodies (anti-active ERK1/2 1:5,000, anti-phospho-
Akt [Ser473] 1:1,000 and anti-phospho-Trk [Tyr 490] 1:1,000
in TBS-T 1% low fat milk; anti-phospho-PLCg 1:750 in TBS-T
5% BSA) was carried out overnight at 48C or for 1 hr at room
temperature. After extensive washing, the membranes were in-
cubated with an alkaline phosphatase-linked secondary antibody
(1:20,000 in TBS-T 1% low fat milk). Protein immunoreactive
bands were visualized by ECF on a Storm 860 Gel and Blot
Imaging System (Amersham Biosciences), after incubation of the
membranes with ECF reagent for 5 min.
Biotinylation Experiments
Plasma membrane synaptosomal proteins were biotinyl-
ated essentially as described previously (Gomes et al., 2004).
Synaptosomes purified by Percoll gradients (2 mg protein/ml)
were pre-incubated for 40 min at 378C in incubation me-
dium. After a 5-min incubation in reaction medium at 378C,
synaptosomes were pelleted and placed on ice. The nerve ter-
minals were resuspended in ice-cold PBS/Ca2þ/Mg2þ con-
taining 1 mg/ml sulfo-NHS-SS-biotin, and incubated for
30 min at 48C. Synaptosomes were washed twice in PBS/
Ca2þ/Mg2þ with 100 mM glycine to remove the excess of
biotin, and washed once again in PBS/Ca2þ/Mg2þ. Supple-
mented RIPA buffer was used to lyse the nerve terminals fol-
lowing the same procedure described above for hippocampal
neurons. The lysates were precipitated twice with UltraLink
Plus immobilized streptavidin beads for 2 hr at 48C, to con-
firm that all biotinylated protein was precipitated. Streptavidin
precipitates were washed with RIPA buffer and eluted with
sample buffer (62.5 mM Tris, 50 mM glycine, 2% SDS, 100
mM DTT, 10% glycerol, 1.5 mM sodium orthovanadate and
0.0005% bromophenol blue). The supernatants were concen-
trated by centrifugation at 13,500 3 gmax for 1 hr 45 min at
48C in Microcon YM-3 centrifugal filter devices, or left in
the original concentration. After denaturation, the whole vol-
ume of the precipitates and the concentrated supernatant, or
one-eighth of the total volume of the supernatant in the origi-
nal concentration, were loaded and separated in 6% SDS-
PAGE and immunoblotted as described above with the mouse
anti-TrkB antibody (1:750 in TBS-T 1% low fat milk). The
use of different concentrations of the supernatant allowed us
to confirm the reliability of the quantification method.
Subsynaptic Fractionation
The separation of the presynaptic active zone, postsy-
naptic density, and non-synaptic fractions from hippocampal
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nerve terminals was carried out essentially as described initially
by Phillips et al. (2001). Briefly, purified synaptosomes were
diluted 1:10 in cold 0.1 mM CaCl2. An equal volume of 23
solubilization buffer (2% Triton X-100, 40 mM Tris, pH 6.0)
was added, and after 30 min of incubation on ice the resulting
insoluble synaptic junctions were pelleted by spinning at
100,000 3 gav for 30 min at 48C. The supernatant (extrasyn-
aptic fraction) was decanted and proteins were precipitated
with 6 vol of acetone at 208C, and recovered by centrifuga-
tion at 18,000 3 gav for 30 min at 158C. The insoluble pel-
let was resuspended and incubated for 30 min in 10 vol of
cold solubilization buffer at pH 8.0 to promote the dissocia-
tion of the extracellular matrix and hence the separation of
the presynaptic active zone from the postsynaptic density. A
centrifugation step precipitated the postsynaptic density, which
is insoluble at 1% Triton X-100. The solubilized presynaptic
active zone proteins, present in the supernatant, were precipi-
tated and recovered as described for the extrasynaptic fraction.
All precipitated fractions were solubilized in 5% SDS and the
protein concentration was determined by the BCA method
(Smith et al., 1985). The samples were denatured with 23
sample buffer and stored at 208C. The protease inhibitor
PMSF was present in all extraction steps. Samples were
probed with the rabbit anti-TrkB (1:500) using the immuno-
blotting procedure described previously.
Immunocytochemistry
Percoll purified synaptosomes were resuspended in
HEPES buffer, allowed to adhere to poly-L-lysine-coated cov-
erslips and processed for immunocytochemistry as described
previously (Diaz-Hernandez et al., 2002). Briefly, synapto-
somes were fixed with 4% paraformaldehyde and incubated
with 0.1% Triton X-100, 3% BSA, and 5% calf serum in
PBS, for 1 hr at room temperature. The coverslips were then
washed and incubated with the primary antibodies in PBS
with 3% BSA and 5% normal rat serum (rabbit anti-TrkB
1:500, mouse anti-TrkB 1:50, guinea pig anti-VGluT1 or
anti-VGluT2 1:5,000, mouse anti-synaptophysin 1:100, and
rabbit anti-syntaxin 1A 1:200). After washing with 3% BSA in
PBS, the synaptosomes were incubated with Alexa 488 anti-
rabbit, Alexa 594 anti-mouse, and Alexa 594 anti-guinea pig
secondary antibodies. After the last washing steps, coverslips
were mounted with Prolong Antifade mounting medium and
visualized using a Zeiss Axiovert 200 inverted microscope
equipped with a cooled CCD camera. The resulting images
were analyzed with MetaFluor 4.0 software.
Statistical Analysis
Results are presented as means 6 SEM of the indicated
number of experiments. Statistical significance was determined
using two-tailed t-test or one-way ANOVA followed by
Newman-Keuls or Dunnett post-tests, as indicated.
RESULTS
BDNF Stimulates [3H]Glutamate Release From
Hippocampal Nerve Terminals
A putative role for BDNF in the modulation of
glutamate release from adult rat hippocampal synapto-
somes was studied using superfused nerve terminals
loaded previously with [3H]glutamate. Under these con-
ditions, depolarization with 20 mM KCl for 30 sec was
previously shown to induce Ca2þ-dependent release of
[3H]glutamate that represented about 90% of the total
tritium released, as determined by HPLC (Lopes et al.,
2002). Two consecutive stimulations with 20 mM KCl
(S1 and S2), separated by 6 min, induced the release of
about the same amount of glutamate, with an S2/S1 ratio
Fig. 1. BDNF potentiates KCl-evoked glutamate release from hippo-
campal nerve terminals. A: Time course of tritium release from hip-
pocampal synaptosomes subjected to two periods of depolarization
(30 sec each) with 20 mM KCl (horizontal bars) separated by 6 min.
Where indicated 100 ng/ml BDNF was added to the superfusate. B:
Average effect of BDNF on Kþ-evoked [3H]glutamate release in S2.
The results are the average 6 SEM of four independent experiments,
carried out using independent preparations. Statistical significance was
determined using the paired Student’s t-test. *P < 0.05.
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of 0.92 6 0.03 (n ¼ 4). When synaptosomes were
superfused with BDNF (100 ng/ml) for 2 min before
the second depolarization pulse with KCl (S2) there was
a significant (P < 0.05) increase in the evoked release of
[3H]glutamate, to 125.6 6 6.0% of the control (Fig. 1).
These results indicate that BDNF acts presynaptically to
modulate glutamate release.
BDNF Activates TrkB But Does Not Significantly
Activate ERK or Akt in Hippocampal Nerve
Terminals
To confirm the presence of BDNF-sensitive Trk
receptors in hippocampal synaptosomes, denatured sam-
ples of Percoll purified nerve terminals, incubated with
BDNF for 1, 4, or 30 min, were probed with anti-phos-
pho-Trk (Tyr 490) antibody, which recognizes the acti-
vated form of Trk receptors (Fig. 2). BDNF, at the con-
centration of 100 ng/ml, increased TrkB phosphoryla-
tion by about four-fold after just 1 min of incubation,
and to more than six-fold after 4 and 30 min. These
results show that TrkB can be phosphorylated and hence
activated in response to BDNF in hippocampal nerve
terminals.
We next investigated whether TrkB phosphoryla-
tion in response to BDNF resulted in the activation of
downstream signaling pathways. BDNF-stimulated puri-
fied nerve terminals were probed for their content on the
phosphorylated forms of ERK1/2, Akt and PLCg (Fig. 3,
pERK, pAkt, and pPLCg). A certain level of ERK phos-
phorylation was found for both isoforms (ERK1/p44 and
ERK2/p42) in control conditions (Fig. 3A), using an anti-
body against the dually phosphorylated (presumably
active) form of ERK, as previously demonstrated in hip-
pocampal synaptosomes (Pereira et al., 2002). BDNF, at
100 ng/ml, was unable to significantly increase ERK1/2
phosphorylation (Fig. 3B). Quantitative results are shown
only for the ERK2 isoform because phosphorylation of
both isoforms varied in a similar manner. Akt phosphoryla-
tion, which occurs downstream of PI3-K activation, was
not significantly affected by incubating nerve terminals
with BDNF for several durations, as shown in the repre-
Fig. 2. BDNF induces Trk phosphorylation in hippocampal synapto-
somes. Percoll purified synaptosomes were incubated with 100 ng/ml
BDNF for 1, 4, or 30 min. Samples were immunoblotted and probed
with anti-phospho-Trk (Tyr 490) as described in Materials and Meth-
ods. A: Representative Western blot. B: Quantitative analysis of three
independent experiments carried out using different preparations. Data
is presented as mean fold increase in pTrk immunoreactivity 6 SEM.
Statistical significance was determined by one-way ANOVA followed
by the Dunnett comparison test, comparing each BDNF stimulated
condition with the control. *P < 0.05, **P < 0.01.
Fig. 3. BDNF activates PLCg but is without effect on the phosphoryl-
ation of ERK and Akt in hippocampal synaptosomes. Percoll purified
synaptosomes were incubated with 100 ng/ml BDNF for 1, 4, or
30 min and probed for their content in the phosphorylated forms of
ERK1/2 (pERK), Akt (pAkt), and PLCg (pPLC) (A). The quantitative
analysis of 3–10 independent experiments for each set of immunoblots,
carried out in different preparations: (B) phosphorylation of ERK2,
(C) PLCg, (D) Akt. Data is presented as mean fold increase in phos-
phorylation 6 SEM. Statistical significance was determined by one-
way ANOVA followed by the Dunnett comparison test (*P < 0.05,
**P < 0.01). Unless otherwise indicated, comparisons were made
between indicated conditions and the control condition.
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sentative blot (Fig. 3A) and in the quantitative analysis plot
(Fig. 3D).
In contrast to the lack of effect of BDNF on ERK
and Akt signaling pathways, PLCg phosphorylation in-
creased approximately two-fold after a 4-min incubation
of hippocampal synaptosomes with 100 ng/ml BDNF
(Fig. 3A,C), and slightly decreased thereafter (Fig. 3A,
C; BDNF 30 min). BDNF-induced PLCg activation in
hippocampal synaptosomes was completely abolished by
the Trk kinase inhibitor K-252a, at the concentration of
200 nM (Berg et al., 1992; Tapley et al., 1992) (Fig.
4A,B). This suggests that PLCg phosphorylation in
response to BDNF was indeed mediated by the TrkB
receptor.
To confirm that the BDNF used in these studies
was able to activate all TrkB initiated signaling pathways
in a different system, we probed BDNF-stimulated hip-
pocampal neuron cultures for pERK, pAkt, and pPLCg.
BDNF induced Akt phosphorylation (approximately 5-
and 4-fold, for 15 and 30 min stimulation, respectively;
Fig. 5A,C) and massive phosphorylation of ERK
(approximately 25- and 15-fold for 15 and 30 min stim-
ulation, respectively; Fig. 5A,B) in cultured hippocampal
neurons. In the same cell culture, PLCg phosphorylation
was increased by eight- and six-fold, after 15- and 30-
min incubations with BDNF, respectively (Fig. 5A,D).
These results confirm that the BDNF used in this study
was capable of fully inducing the activation of the ERK,
Fig. 4. K-252a inhibits BDNF-induced PLCg phosphorylation. Puri-
fied synaptosomes were incubated with 100 ng/ml BDNF for 4 min
in the presence or absence of 200 nM K-252a (applied 10 min before
BDNF application). A: Representative immunoblot against pPLCg.
B: Quantification of three independent immunoblots obtained using
different preparations. Data is presented as mean fold activation 6
SEM and statistical significance was determined by one-way ANOVA
followed by Dunnett comparison test between each condition and
the control condition (Ctr). **P < 0.01.
Fig. 5. BDNF extensively activates the ERK, PI3-K and PLCg path-
ways in hippocampal primary cultures. Hippocampal neurons were
stimulated for 15 or 30 min with 100 ng/ml BDNF as described in
Materials and Methods. A: Representative blots of three to four in-
dependent experiments for pERK, pAkt, and pPLCg detection.
Quantitative results for the phosphorylation of ERK (B), Akt (C),
and PLCg (D) induced by BDNF, are shown as mean fold increase
in phosphorylation 6 SEM, for the indicated number of experiments
carried out in different preparations. Statistical significance was deter-
mined by one-way ANOVA followed by Dunnett comparison test
between each condition and control condition. *P < 0.05, **P <
0.01.
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Akt and PLCg pathways in cultured hippocampal neu-
rons. The comparison of the amplitude of the BDNF-
induced activation of these signaling pathways in cultured
neurons and purified synaptosomes suggests that the effects
of BDNF are minimal in the overall population of hippo-
campal nerve terminals, correlating with the small effect
on glutamate release in nerve endings.
TrkB Is Absent in More Than Two-Thirds of
Adult Hippocampal Glutamatergic Nerve
Terminals
The small effect of BDNF on KCl-evoked glutamate
release, and in stimulating TrkB downstream signaling
pathways in hippocampal synaptosomes lead us to examine
the percentage of nerve terminals that are endowed with
TrkB in the adult hippocampus. Synaptosomes were plated
on poly-L-lysine-coated coverslips and processed for im-
munocytochemistry as described in Materials and Meth-
ods. Antibodies against synaptophysin (Fig. 6) and syntaxin
1A (data not shown), presynaptic vesicle and plasma mem-
brane proteins, respectively, were used as presynaptic
markers. TrkB receptors were labeled with two different
anti-TrkB antibodies that recognize the full-length and
the truncated forms of the receptor (Fig. 6 and data not
shown). As shown in Figure 6 A–C, rabbit anti-TrkB and
mouse anti-synaptophysin staining co-localized partially
(arrowheads in Fig. 6C). However, a quantification of these
images showed that approximately 70% of synaptophysin-
labeled structures lacked TrkB labeling (Table I). Similar
results were obtained with rabbit anti-syntaxin 1A and
mouse anti-TrkB antibodies (data not shown). These data
suggest that only about one-third of presynaptic terminals
in the adult rat hippocampus are endowed with TrkB
receptors.
It is important to realize that >90% of TrkB-labeled
structures were also synaptophysin-positive (Fig. 6A–C,
Table I). This suggests that this purified synaptosomal
preparation is mostly devoid of postsynaptic contaminating
structures, or that TrkB receptors are confined to nerve
terminals at the synapse. The former hypothesis seems
Fig. 6. TrkB is present in less than one-third of synaptophysin- or
VGluT-positive nerve terminals. Percoll purified synaptosomes were
plated on poly-L-lysine-coated coverslips, processed for immunocyto-
chemistry and visualized by fluorescence microscopy as described in Mate-
rials and Methods. Representative images of three to eight independent
experiments are shown. Each row of three panels represents a double-
staining experiment, where the third panel depicts the merge of the previ-
ous two. Synaptosomes showing co-localization of both red and green fluo-
rescence are marked by arrowheads. Synaptophysin (Syn), TrkB,
VGluT1, and VGluT2 immunoreactivities are indicated in each panel.
TABLE I. Quantification of the Fraction of Adult Hippocampal
Nerve Terminals (Total or Glutamatergic) Expressing TrkB and




VGluT1 35.3 6 6.5
VGluT2 14.9 6 7.3
VGluT1 and 2 39.5 6 5.4
TrkB-positive structures containing:
VGluT1 38.3 6 4.4
VGluT2 13.0 6 2.5
VGluT1 and 2 52.4 6 4.6
Synaptophysin 95.4 6 2.6
Structures containing TrkB:
VGluT1 31.9 6 2.1
VGluT2 25.7 6 3.5
VGluT1 and 2 31.2 6 3.2 (n ¼ 8)
Synaptophysin 29.2 6 3.3 (n ¼ 6)
*All values are mean 6 SEM of the experiments, and are the quantifica-
tion of the data represented in Figure 6. n ¼ 3 experiments unless indi-
cated.
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likely because staining with an anti-PSD-95 antibody did
not yield any significant signal (data not shown).
We next investigated the presence of TrkB in gluta-
matergic presynaptic terminals. The VGluT1 and VGluT2
isoforms of vesicular glutamate transporters have been
used as glutamatergic nerve terminal markers because: 1)
all glutamatergic synapses, possess either VGluT1 or VGluT2
(Fremeau et al., 2001); 2) the presence of VGluT1 or
VGluT2 in non-glutamatergic neurons is sufficient to de-
fine a glutamatergic phenotype (Takamori et al., 2000,
2001); and 3) VGluT1 and VGluT2 are predominantly lo-
cated at nerve terminals, in synaptic vesicles, with few or
no overlap (Herzog et al., 2001).
As expected, VGluT1 and VGluT2 strongly co-lo-
calized with synaptophysin (Fig. 6D–I, arrowheads).
Moreover, about 35% and 15% of synaptophysin-positive
structures were VGluT1- and VGluT2-positive, respec-
tively (Fig. 6F,I, Table I), confirming that most hippo-
campal glutamatergic nerve terminals express VGluT1.
The amount of synaptophysin-positive structures contain-
ing VGluT1 was not significantly different from the
amount of synaptophysin-positive structures containing
either VGluT1 or VGluT2 (approximately 40%; Table I;
P > 0.05, as determined by one-way ANOVA with Bon-
ferroni test). These results suggest that approximately 40%
of adult hippocampal nerve terminals are glutamatergic
and that a fraction of these glutamatergic terminals express
both VGluT1 and VGluT2.
Only about one-third of VGluT1-containing termi-
nals and one-fourth of VGluT2-immunoreactive ones
were TrkB-positive (Fig. 6J–O, Table I). The results shown
in Figure 6J–O were obtained using the rabbit anti-TrkB
antibody and they were reproduced using two other anti-
Trk antibodies (the mouse anti-Trk [E7] and the mouse
anti-TrkB; data not shown). When all glutamatergic termi-
nals were stained by using anti-VGluT1 and anti-VGluT2
antibodies, simultaneously, we observed that TrkB was
present in approximately one-third of them (Fig. 6P–R,
Table I). Among the whole population of TrkB-positive
structures, close to 40% were VGluT1-positive and about
10% were VGluT2-positive (Fig. 6J–O, Table I), whereas
approximately 50% were labeled with either VGluT1 or
VGluT2 (Fig. 6P–R, Table I). These results suggest that
only one-third of the adult hippocampal glutamatergic
terminals express TrkB whereas only half of presynaptic
TrkB is confined to glutamatergic terminals in the adult
hippocampus. This may explain the small effect of BDNF
on the overall glutamate release (Fig. 1) and TrkB down-
stream signaling, measured using the whole synaptosomal
population.
Full-Length TrkB Receptors Are Distributed in
Pre-, Post-, and Extrasynaptic Sites and Are
Mostly Located Intracellularly
We further investigated the expression and distri-
bution of TrkB at adult hippocampal synapses using two
approaches. First, we followed a fractionation procedure
described previously that allows the separation of pro-
teins from the presynaptic active zone and the postsyn-
aptic density from proteins present in other parts of the
synapse. Second, we determined the percentage of TrkB
receptors located at the plasma membrane and at intra-
cellular locations in hippocampal synaptosomes, by tag-
ging extracellular proteins with biotin.
Subsynaptic fractionation was carried out by ex-
tracting synaptosomes sequentially with 1% Triton X-100
at pH 6.0 followed by pH 8.0. Triton X-100 solubilizes
most synaptosomal components with the exception of the
‘‘synaptic junction,’’ which contains the presynaptic active
zone, the postsynaptic density, and interlinked transmem-
brane adhesion molecules. The presynaptic active zone is
then solubilized by increasing the pH to 8.0 (Materials and
Methods; Phillips et al., 2001). This procedure has been
shown previously to separate pre-, post-, and extrasynaptic
markers with over 90% efficiency (Pinheiro et al., 2003;
Rebola et al., 2003). Full-length (p145) and truncated
TrkB (p95) showed a differential distribution among the
three subsynaptic fractions (Fig. 7A,B). The majority of
both TrkB isoforms was found in the extrasynaptic frac-
tion, which includes intracellular and plasma membrane
proteins that are excluded from the synaptic junction.
However, approximately 35% of full length TrkB was
evenly distributed between the presynaptic active zone
and the postsynaptic density, whereas truncated TrkB was
absent from the postsynaptic density (Fig. 7A,B). A small
10% fraction of the total truncated isoform was also pres-
ent at the presynaptic active zone (Fig. 7A,B).
The isolation of subsynaptic fractions showed that the
majority of TrkB receptors are excluded from the synaptic
junction, but it did not clarify whether they are present at
the plasma membrane, away from the active zone, or at in-
tracellular locations. To address this question, proteins
located at the plasma membrane were tagged with biotin
and precipitated with streptavidin beads. Biotinylated sam-
ples were precipitated twice to test for the efficiency of the
process. Both precipitates and supernatants were probed
for their content in TrkB. Biotinylated proteins from the
first precipitation contained the full-length and truncated
forms of the receptor (Fig. 7C). The second precipitation
did not significantly recover any of the TrkB isoforms,
confirming the efficiency of the first streptavidin precipita-
tion (Fig. 7C). The immunoreactivity showed in the su-
pernatant lane for p145 and p95 TrkB corresponds to one-
eighth of the total immunoreactivity present in the super-
natant because only one-eighth of the total volume was
probed (Fig. 7C). In some cases, the supernatant samples
were concentrated by centrifugation on centrifugal filter
devices so that the total volume of the supernatant could
be probed. This allowed us to test for the reliability of the
quantification method. We found that only about 25% of
total full-length TrkB present in this synaptosomal prepara-
tion was biotinylated (Fig. 7D). However, the percentage
of biotinylated truncated TrkB was significantly higher
than biotinylated p145, reaching nearly 50% (Fig. 7D).
These data indicate that the majority of TrkB pres-
ent at the Percoll purified hippocampal nerve terminal
preparation is located intracellularly.
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DISCUSSION
We present evidence supporting the presence of
TrkB receptors in only about one-third of glutamatergic
hippocampal nerve terminals from adult rats. This corre-
lates with the small effect of BDNF on the phosphoryla-
tion of PLCg and on KCl-evoked glutamate release
from the whole population of hippocampal synapto-
somes. Furthermore, only 25% of full-length TrkB pres-
ent in this synaptosomal preparation was located at the
plasma membrane, evenly distributed among the presyn-
aptic active zone and the postsynaptic density, further
explaining the small effect of BDNF on the overall glu-
tamate release. Taken together, however, our data sug-
gest that BDNF may have a much stronger effect on
glutamate release from the small population of terminals
endowed with TrkB at the plasma membrane.
Approximately 30% of adult hippocampal glutama-
tergic nerve terminals, possessing simultaneously VGluT1
and VGluT2, were positive for TrkB receptors in this
study. A similar result was obtained for the overall hip-
pocampal nerve terminal preparation (Fig. 6). These are
higher percentages than reported previously by Drake
et al. (1999), where less than one in 200 presynaptic
profiles (axons and terminals) were immunoreactive to
p145 TrkB, as assessed by immunoelectron microscopy.
That was considered to be an underestimation of the
actual number of labeled terminals because TrkB immu-
noreactivity was not present in most planes of section.
Because the immunocytochemistry of isolated nerve ter-
minals allows the visualization of TrkB staining in the
whole terminal, this might generate a more precise
quantification of TrkB-positive terminals.
Only one-fourth of total full length TrkB was lo-
cated at the plasma membrane in our purified synaptoso-
mal preparation. Although we cannot rule out the possi-
bility that the receptor is internalized during the prepara-
tion of synaptosomes, our findings are in agreement with
a previous report showing that most TrkB receptors are
located intracellularly in many regions of adult hippocam-
pal neurons, including at nerve terminals (Drake et al.,
Fig. 7. Full-length TrkB localization at the adult hippocampal syn-
apse: pre- and postsynaptic, but mostly intracellular. A,B: Subsynap-
tic fractionation of purified hippocampal synaptosomes was carried
out as described in Materials and Methods to obtain presynaptic
active zone (pre), postsynaptic density (post), and extrasynaptic (extra)
fractions. These fractions were immunoblotted and probed with a
rabbit anti-TrkB antibody that recognizes the full-length (p145) and
the truncated (p95) form of the receptor. A representative membrane
is shown in (A) whereas (B) depicts the quantification of three inde-
pendent experiments. Data is presented as mean % of total p145 or
p95 TrkB immunoreactivity 6 SEM. C,D: Purified hippocampal
synaptosomes were incubated with sulfo-NHS-SS-biotin to tag plasma
membrane proteins, and precipitated twice with streptavidin beads (Mate-
rials and Methods). C: Representative immunoblot showing p145
and p95 TrkB present in the total volume of the first (PP #1) and
the second (PP #2) precipitates, and in one-eighth of the total super-
natant (S/8). D: Quantification of seven independent experiments
representing the mean % of biotinylated TrkB 6 SEM. Each experi-
ment was carried out using a different synaptosomal preparation.
Total TrkB was calculated by adding the value for precipitated TrkB
to the value for supernatant TrkB multiplied by 8. In some experi-
ments, the total supernatant was probed, after concentrating the sam-
ples. In this case, total TrkB was calculated simply by adding precipi-
tated and supernatant TrkB values.
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1999). These results do not clarify, though, the percentage
of nerve terminals that express p145 TrkB at the surface.
Nevertheless, these data suggest that, within the small frac-
tion of TrkB-positive glutamatergic nerve terminals, the
percentage of terminals capable of responding to BDNF
may be even smaller due to the small percentage of TrkB
receptors present at the plasma membrane. The amplitude
of the responses to BDNF in vivo may change depending
on the recent history of the terminal because plasma mem-
brane depolarization and cAMP elevation rapidly increase
the amount of TrkB receptors associated with the plasma
membrane of CNS neurons (Meyer-Franke et al., 1998).
An interesting difference in the location of full length
and truncated TrkB receptors resides in their subsynaptic
distribution. Although approximately 35% of p145 TrkB
receptors were evenly distributed between the presynaptic
active zone and the postsynaptic density, the truncated
isoform was absent from the postsynaptic density and only
10% was present at the presynaptic active zone (Fig. 7).
Because only about 25% of full-length TrkB was present
at the plasma membrane, this suggests that all extrasynaptic
p145 TrkB is intracellular. About half of p95 TrkB was at
the plasma membrane indicating that a significant fraction
of the extrasynaptic truncated isoform is located there.
This confinement of the catalytically active TrkB receptor
to the active zone is very interesting considering the
known effects of BDNF on synaptic transmission and plas-
ticity discussed below. The absence of the truncated re-
ceptor at the postsynaptic density, reported previously in
adult rat brain (Kryl et al., 1999; Xu et al., 2000), raises
the question of the precise function of p95 TrkB: does it
work simply as a BDNF scavenger, or does it mediate a
synaptic response independently of p145 TrkB, as sug-
gested for other cellular outcomes (Baxter et al., 1997;
Yacoubian and Lo, 2000; Rose et al., 2003), which is de-
pendent on its specific location?
Application of BDNF to isolated hippocampal
nerve terminals increased TrkB phosphorylation, show-
ing that TrkB receptors located at the synaptosomal
plasma membrane can be activated by its ligand. The
lack of effect of BDNF on ERK and Akt phosphoryla-
tion in the overall nerve terminal population is probably
due to the reduced number of terminals that express
TrkB at the plasma membrane. Thus, the eventual ERK
and Akt activation triggered by TrkB in a limited num-
ber of terminals was probably undetectable above the ba-
sal activation of these molecules in the whole population
of terminals. BDNF was still able to significantly stimu-
late PLCg phosphorylation, which is interesting because
PLCg is involved in BDNF-induced potentiation of
depolarization-evoked exocytotic glutamate release in
cultured cortical neurons (Matsumoto et al., 2001). This
suggests that the basal phosphorylation of this protein is
sufficiently low to allow the detection of an increase in
phosphorylation of a small percentage of the total PLCg.
The small fraction of glutamatergic nerve terminals
that are endowed with TrkB at the plasma membrane,
accessible to its specific ligands, accounts for the small
effect of BDNF on the average [3H]glutamate release
(about 25% increase) from a population of hippocampal
synaptosomes. This effect of BDNF was not observed in
a previous study, where the effect of the neurotrophin
on KCl-evoked release of endogenous glutamate from
dentate gyrus synaptosomes was investigated, possibly
due to the lower sensitivity of the method used. In this
case, however, BDNF was shown to act synergistically
with the metabotropic glutamate receptor agonist
(1S,3R)ACPD to potentiate KCl-evoked glutamate re-
lease, to a small extent (Gooney and Lynch, 2001).
These findings and our own results contrast with the
large effect of BDNF on [3H]glutamate release from hip-
pocampal synaptosomes isolated from 3-week-old rats,
where the neurotrophin potentiated neurotransmitter
release evoked by KCl-depolarization to about 400% of
the control (Canas et al., 2004). It would be interesting
to know the percentage of TrkB-positive glutamatergic
synaptosomes in developing rats, to determine whether a
change in the glutamatergic nerve terminals expressing
TrkB at the plasma membrane may account for the
observed differences.
BDNF was also shown to potentiate 4-AP-evoked
glutamate release from cerebrocortical synaptosomes in a
synapsin I/II-dependent manner, probably by a mecha-
nism involving ERK (Jovanovic et al., 2000; but see
also Pereira et al., 2002). Forebrain synaptosomes of TrkB
(/) mice show reduced levels of Ca2þ-dependent
neurotransmitter release in response to Kþ-depolarization
(Carmona et al., 2003). This suggests that TrkB recep-
tors are also present in the forebrain and cerebral cortex,
where they modulate glutamate release.
BDNF was also shown to induce a long-lasting po-
tentiation of evoked field excitatory postsynaptic potentials
(EPSPs) in the CA1 region by acting presynaptically
(Kang and Schuman, 1995), an effect that has not been
confirmed by other laboratories (Figurov et al., 1996; Pat-
terson et al., 1996; Tanaka et al., 1997; Frerking et al.,
1998; Gottschalk et al., 1998). Although field EPSPs have
the contribution of more than one synapse, based on the
low number of TrkB-positive glutamatergic terminals dem-
onstrated, one would predict a certain amount of failure to
occur in BDNF-induced synaptic potentiation in this sys-
tem. Therefore, our findings rather support the results by
others showing an increase in field EPSPs after BDNF
application in only 1 of 11 experiments (Frerking et al.,
1998).
Several reports demonstrate that the involvement
of BDNF in Schaffer collateral-CA1 synaptic LTP is at
least partially achieved through presynaptic modifica-
tions, such as the reduction of synaptic fatigue by in-
creasing the number of docked vesicles at the active
zone (Figurov et al., 1996; Pozzo-Miller et al., 1999;
Tyler and Pozzo-Miller 2001; Xu et al., 2000). How
does this correlate with the small percentage of glutama-
tergic terminals that express TrkB at the plasma mem-
brane? A putative increase in surface TrkB could be
achieved after LTP-inducing high frequency stimulation,
similarly to what was described for cultured hippocampal
neurons (Du et al., 2000). A recruitment of TrkB recep-
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tors to presynaptic terminals, resulting in an augmented
number of TrkB-positive glutamatergic terminals would
be an interesting mechanism, although no evidence sug-
gests it so far. Another possibility would be the involve-
ment of postsynaptic TrkB receptors in the modulation
of LTP by BDNF, as previously suggested (Tyler and
Pozzo-Miller, 2001; Kovalchuk et al., 2002). This would
predict the existence of a BDNF/TrkB-induced retro-
grade messenger that would carry out the presynaptic
modifications attributed to BDNF during LTP. Selective
genetic ablation of TrkB receptors at the CA1 region
does not reduce LTP, however, suggesting that postsyn-
aptic TrkB receptors are dispensable for LTP at the
Schaffer collateral-CA1 synapses (Xu et al., 2000). Dif-
ferent LTP-inducing protocols are also modulated differ-
entially by BDNF (Figurov et al., 1996; Kang et al.,
1997; Patterson et al., 2001), and, therefore, the relative
importance of presynaptic or postsynaptic TrkB receptors
may vary accordingly.
Approximately half of TrkB-positive adult hippo-
campal nerve terminals were not stained with glutamater-
gic markers (Fig. 6, Table I). This suggests that non-gluta-
matergic synapses might also be possible targets for BDNF
in the hippocampus. In fact, BDNF enhances acetylcho-
line release from adult hippocampal synaptosomes (Knip-
per et al., 1994), and reduces GABAA-mediated inhibitory
postsynaptic currents in adult hippocampal slices through
presynaptic and postsynaptic mechanisms (Tanaka et al.,
1997; Frerking et al., 1998; Olofsdotter et al., 2000). It
would be interesting to investigate the percentage of cho-
linergic and GABAergic terminals that express TrkB.
In conclusion, our data show that only one-third of
presynaptic glutamatergic nerve terminals express TrkB in
the adult hippocampus. Within those terminals, an even
lower percentage of this receptor is present at the plasma
membrane, accessible to its ligands because 75% of full-
length TrkB receptors are located intracellularly. This
implies that BDNF does not modulate neurotransmitter
release in the majority of these terminals, supporting a re-
stricted synapse-specific action of BDNF in the modula-
tion of glutamate release. Further studies will be required
to relate TrkB synapse-specific expression with the state of
synapse maturation and long term synaptic strengthening.
ACKNOWLEDGMENTS
We would like to express our gratitude to Regen-
eron Pharmaceuticals Inc. (Tarrytown, NY) for provid-
ing us with BDNF, and to Dr. J. Blasi for the syntaxin
1A antibody. We would also like to thank E. Carvalho
for excellent technical assistance.
REFERENCES
Alder J, Thakker-Varia S, Crozier RA, Shaheen A, Plummer MR, Black
IB. 2005. Early presynaptic and late postsynaptic components contribute
independently to brain-derived neurotrophic factor-induced synaptic
plasticity. J Neurosci 25:3080–3085.
Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos
MM, Carvalho RF, Carvalho AP, Duarte CB. 2005. Neuroprotection
by BDNF against glutamate-induced apoptotic cell death is mediated
by ERK and PI3-kinase pathways. Cell Death Differ 12:1329–1343.
Baxter GT, Radeke MJ, Kuo RC, Makrides V, Hinkle B, Hoang R, Me-
dina-Selby A, Coit D, Valenzuela P, Feinstein SC. 1997. Signal transduc-
tion mediated by the truncated trkB receptor isoforms, trkB.T1 and trkB.T2.
J Neurosci 17:2683–2690.
Berg MM, Sternberg DW, Parada LF, Chao MV. 1992. K-252a inhibits
nerve growth factor-induced trk proto-oncogene tyrosine phosphoryla-
tion and kinase activity. J Biol Chem 267:13–16.
Berninger B, Schinder AF, Poo MM. 1999. Synaptic reliability correlates
with reduced susceptibility to synaptic potentiation by brain-derived
neurotrophic factor. Learn Mem 6:232–242.
Canas N, Pereira IT, Ribeiro JA, Sebastiao AM. 2004. Brain-derived neu-
rotrophic factor facilitates glutamate and inhibits GABA release from hip-
pocampal synaptosomes through different mechanisms. Brain Res 1016:
72–78.
Carmona MA, Martinez A, Soler A, Blasi J, Soriano E, Aguado F. 2003.
Ca2þ-evoked synaptic transmission and neurotransmitter receptor levels
are impaired in the forebrain of trkb (/) mice. Mol Cell Neurosci
22:210–226.
Chao MV. 2003. Neurotrophins and their receptors: a convergence point
for many signalling pathways. Nat Rev Neurosci 4:299–309.
Diaz-Hernandez M, Pereira MF, Pintor J, Cunha RA, Ribeiro JA,
Miras-Portugal MT. 2002. Modulation of the rat hippocampal dinucleo-
tide receptor by adenosine receptor activation. J Pharmacol Exp Ther
301:441–450.
Drake CT, Milner TA, Patterson SL. 1999. Ultrastructural localization of
full-length trkB immunoreactivity in rat hippocampus suggests multiple
roles in modulating activity-dependent synaptic plasticity. J Neurosci 19:
8009–8026.
Du J, Feng L, Yang F, Lu B. 2000. Activity- and Ca2þ-dependent mod-
ulation of surface expression of brain-derived neurotrophic factor recep-
tors in hippocampal neurons. J Cell Biol 150:1423–1434.
Dunkley PR, Jarvie PE, Heath JW, Kidd GJ, Rostas JA. 1986. A rapid
method for isolation of synaptosomes on Percoll gradients. Brain Res
372:115–129.
Ernfors P, Wetmore C, Olson L, Persson H. 1990. Identification of cells
in rat brain and peripheral tissues expressing mRNA for members of
the nerve growth factor family. Neuron 5:511–526.
Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. 1996. Regula-
tion of synaptic responses to high-frequency stimulation and LTP by
neurotrophins in the hippocampus. Nature 381:706–709.
Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer
RJ, Bellocchio EE, Fortin D, Storm-Mathisen J, Edwards RH. 2001.
The expression of vesicular glutamate transporters defines two classes of
excitatory synapse. Neuron 31:247–260.
Frerking M, Malenka RC, Nicoll RA. 1998. Brain-derived neurotrophic
factor (BDNF) modulates inhibitory, but not excitatory, transmission in
the CA1 region of the hippocampus. J Neurophysiol 80:3383–3386.
Gomes AR, Cunha P, Nuriya M, Faro CJ, Huganir RL, Pires EV, Car-
valho AL, Duarte CB. 2004. Metabotropic glutamate and dopamine
receptors co-regulate AMPA receptor activity through PKA in cultured
chick retinal neurones: effect on GluR4 phosphorylation and surface
expression. J Neurochem 90:673–682.
Goodman LJ, Valverde J, Lim F, Geschwind MD, Federoff HJ, Geller
AI, Hefti F. 1996. Regulated release and polarized localization of brain-
derived neurotrophic factor in hippocampal neurons. Mol Cell Neuro-
sci 7:222–238.
Gooney M, Lynch MA. 2001. Long-term potentiation in the dentate
gyrus of the rat hippocampus is accompanied by brain-derived neuro-
trophic factor-induced activation of TrkB. J Neurochem 77:1198–1207.
Gottschalk W, Pozzo-Miller LD, Figurov A, Lu B. 1998. Presynaptic mod-
ulation of synaptic transmission and plasticity by brain-derived neurotro-
phic factor in the developing hippocampus. J Neurosci 18:6830–6839.
842 Pereira et al.
Journal of Neuroscience Research DOI 10.1002/jnr
Hartmann M, Heumann R, Lessmann V. 2001. Synaptic secretion of
BDNF after high-frequency stimulation of glutamatergic synapses.
EMBO J 20:5887–5897.
Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C,
Gasnier B, Giros B, El Mestikawy S. 2001. The existence of a second
vesicular glutamate transporter specifies subpopulations of glutamatergic
neurons. J Neurosci 21:RC181.
Huang EJ, Reichardt LF. 2003. Trk receptors: roles in neuronal signal
transduction. Annu Rev Biochem 72:609–642.
Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS. 2000.
Synapsins as mediators of BDNF-enhanced neurotransmitter release.
Nat Neurosci 3:323–329.
Kang H, Jia LZ, Suh KY, Tang L, Schuman EM. 1996. Determinants of
BDNF-induced hippocampal synaptic plasticity: role of the Trk B re-
ceptor and the kinetics of neurotrophin delivery. Learn Mem 3:188–
196.
Kang H, Schuman EM. 1995. Long-lasting neurotrophin-induced enhance-
ment of synaptic transmission in the adult hippocampus. Science 267:
1658–1662.
Kang H, Welcher AA, Shelton D, Schuman EM. 1997. Neurotrophins
and time: different roles for TrkB signaling in hippocampal long-term
potentiation. Neuron 19:653–664.
Klein R, Conway D, Parada LF, Barbacid M. 1990. The trkB tyrosine
protein kinase gene codes for a second neurogenic receptor that lacks
the catalytic kinase domain. Cell 61:647–656.
Knipper M, da Penha Berzaghi M, Blochl A, Breer H, Thoenen H,
Lindholm D. 1994. Positive feedback between acetylcholine and the
neurotrophins nerve growth factor and brain-derived neurotrophic fac-
tor in the rat hippocampus. Eur J Neurosci 6:668–671.
Korte M, Griesbeck O, Gravel C, Carroll P, Staiger V, Thoenen H,
Bonhoeffer T. 1996. Virus-mediated gene transfer into hippocampal
CA1 region restores long-term potentiation in brain-derived neurotro-
phic factor mutant mice. Proc Natl Acad Sci USA 93:12547–12552.
Kossel AH, Cambridge SB, Wagner U, Bonhoeffer T. 2001. A caged Ab
reveals an immediate/instructive effect of BDNF during hippocampal
synaptic potentiation. Proc Natl Acad Sci USA 98:14702–14707.
Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A. 2002. Postsynaptic
Induction of BDNF-mediated long-term potentiation. Science 295:1729–
1734.
Kryl D, Yacoubian T, Haapasalo A, Castren E, Lo D, Barker PA. 1999.
Subcellular localization of full-length and truncated Trk receptor iso-
forms in polarized neurons and epithelial cells. J Neurosci 19:5823–
5833.
Lamballe F, Klein R, Barbacid M. 1991. trkC, a new member of the trk
family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell
66:967–979.
Lessmann V, Gottmann K, Heumann R. 1994. BDNF and NT-4/5
enhance glutamatergic synaptic transmission in cultured hippocampal
neurones. Neuroreport 6:21–25.
Lessmann V, Heumann R. 1998. Modulation of unitary glutamatergic
synapses by neurotrophin-4/5 or brain-derived neurotrophic factor in
hippocampal microcultures: presynaptic enhancement depends on pre-
established paired-pulse facilitation. Neuroscience 86:399–413.
Levine ES, Crozier RA, Black IB, Plummer MR. 1998. Brain-derived
neurotrophic factor modulates hippocampal synaptic transmission by
increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad
Sci USA 95:10235–10239.
Levine ES, Dreyfus CF, Black IB, Plummer MR. 1995. Brain-derived
neurotrophic factor rapidly enhances synaptic transmission in hippocam-
pal neurons via postsynaptic tyrosine kinase receptors. Proc Natl Acad
Sci USA 92:8074–8077.
Li YX, Xu Y, Ju D, Lester HA, Davidson N, Schuman EM. 1998a. Ex-
pression of a dominant negative TrkB receptor, T1, reveals a require-
ment for presynaptic signaling in BDNF-induced synaptic potentiation
in cultured hippocampal neurons. Proc Natl Acad Sci USA 95:10884–
10889.
Li YX, Zhang Y, Lester HA, Schuman EM, Davidson N. 1998b.
Enhancement of neurotransmitter release induced by brain-derived neu-
rotrophic factor in cultured hippocampal neurons. J Neurosci 18:10231–
10240.
Lopes LV, Cunha RA, Kull B, Fredholm BB, Ribeiro JA. 2002. Adeno-
sine A2A receptor facilitation of hippocampal synaptic transmission is
dependent on tonic A1 receptor inhibition. Neuroscience 112:319–329.
Matsumoto T, Numakawa T, Adachi N, Yokomaku D, Yamagishi S,
Takei N, Hatanaka H. 2001. Brain-derived neurotrophic factor enhan-
ces depolarization-evoked glutamate release in cultured cortical neu-
rons. J Neurochem 79:522–530.
McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls
DG. 1992. Tetanus toxin and botulinum toxins type A and B inhibit glu-
tamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release
from synaptosomes. Clues to the locus of action. J Biol Chem 267:
21338–21343.
Messaoudi E, Bardsen K, Srebro B, Bramham CR. 1998. Acute intrahip-
pocampal infusion of BDNF induces lasting potentiation of synaptic
transmission in the rat dentate gyrus. J Neurophysiol 79:496–499.
Messaoudi E, Ying SW, Kanhema T, Croll SD, Bramham CR. 2002.
Brain-derived neurotrophic factor triggers transcription-dependent, late
phase long-term potentiation in vivo. J Neurosci 22:7453–7461.
Meyer-Franke A, Wilkinson GA, Kruttgen A, Hu M, Munro E, Hanson
MG, Jr., Reichardt LF, Barres BA. 1998. Depolarization and cAMP
elevation rapidly recruit TrkB to the plasma membrane of CNS neu-
rons. Neuron 21:681–693.
Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, Rossi-
Arnaud C, Lipp HP, Bonhoeffer T, Klein R. 1999. Essential role for TrkB
receptors in hippocampus-mediated learning. Neuron 24:401–414.
Olofsdotter K, Lindvall O, Asztely F. 2000. Increased synaptic inhibition
in dentate gyrus of mice with reduced levels of endogenous brain-
derived neurotrophic factor. Neuroscience 101:531–539.
Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER.
1996. Recombinant BDNF rescues deficits in basal synaptic transmis-
sion and hippocampal LTP in BDNF knockout mice. Neuron 16:
1137–1145.
Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M. 1992. Neuro-
trophin expression in rat hippocampal slices: a stimulus paradigm induc-
ing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neu-
ron 9:1081–1088.
Patterson SL, Pittenger C, Morozov A, Martin KC, Scanlin H, Drake C,
Kandel ER. 2001. Some forms of cAMP-mediated long-lasting poten-
tiation are associated with release of BDNF and nuclear translocation of
phospho-MAP kinase. Neuron 32:123–140.
Pereira DB, Carvalho AP, Duarte CB. 2002. Non-specific effects of the
MEK inhibitors PD098, 059 and U0126 on glutamate release from hip-
pocampal synaptosomes. Neuropharmacology 42:9–19.
Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan
WS, Arndt K, Frank M, Gordon RE, Gawinowicz MA, Zhao Y, Col-
man DR. 2001. The presynaptic particle web: ultrastructure, composi-
tion, dissolution, and reconstitution. Neuron 32:63–77.
Pinheiro PS, Rodrigues RJ, Silva AP, Cunha RA, Oliveira CR, Malva
JO. 2003. Solubilization and immunological identification of presynap-
tic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tors in the rat hippocampus. Neurosci Lett 336:97–100.
Poo MM. 2001. Neurotrophins as synaptic modulators. Nat Rev Neuro-
sci 2:24–32.
Pozzo-Miller LD, Gottschalk W, Zhang L, McDermott K, Du J, Gopa-
lakrishnan R, Oho C, Sheng ZH, Lu B. 1999. Impairments in high-
frequency transmission, synaptic vesicle docking, and synaptic protein
distribution in the hippocampus of BDNF knockout mice. J Neurosci
19:4972–4983.
TrkB in Hippocampal Glutamatergic Terminals 843
Journal of Neuroscience Research DOI 10.1002/jnr
Rebola N, Pinheiro PC, Oliveira CR, Malva JO, Cunha RA. 2003.
Subcellular localization of adenosine A1 receptors in nerve terminals
and synapses of the rat hippocampus. Brain Res 987:49–58.
Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, Cunha RA.
2005. Dual presynaptic control by ATP of glutamate release via facilita-
tory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4
receptors in the rat hippocampus. J Neurosci 25:6286–6295.
Rose CR, Blum R, Pichler B, Lepier A, Kafitz KW, Konnerth A. 2003.
Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling
in glia cells. Nature 426:74–78.
Schinder AF, Berninger B, Poo M. 2000. Postsynaptic target specificity
of neurotrophin-induced presynaptic potentiation. Neuron 25:151–163.
Schuman EM. 1999. Neurotrophin regulation of synaptic transmission.
Curr Opin Neurobiol 9:105–109.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Proven-
zano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. 1985.
Measurement of protein using bicinchoninic acid. Anal Biochem 150:
76–85.
Takamori S, Rhee JS, Rosenmund C, Jahn R. 2000. Identification of a
vesicular glutamate transporter that defines a glutamatergic phenotype
in neurons. Nature 407:189–194.
Takamori S, Rhee JS, Rosenmund C, Jahn R. 2001. Identification
of differentiation-associated brain-specific phosphate transporter as a
second vesicular glutamate transporter (VGLUT2). J Neurosci 21:
RC182.
Tanaka T, Saito H, Matsuki N. 1997. Inhibition of GABAA synaptic
responses by brain-derived neurotrophic factor (BDNF) in rat hippo-
campus. J Neurosci 17:2959–2966.
Tapley P, Lamballe F, Barbacid M. 1992. K252a is a selective inhibitor
of the tyrosine protein kinase activity of the trk family of oncogenes
and neurotrophin receptors. Oncogene 7:371–381.
Tartaglia N, Du J, Tyler WJ, Neale E, Pozzo-Miller L, Lu B. 2001. Pro-
tein synthesis-dependent and -independent regulation of hippocampal
synapses by brain-derived neurotrophic factor. J Biol Chem 276:37585–
37593.
Tyler WJ, Pozzo-Miller LD. 2001. BDNF enhances quantal neurotrans-
mitter release and increases the number of docked vesicles at the active
zones of hippocampal excitatory synapses. J Neurosci 21:4249–4258.
Xu B, Gottschalk W, Chow A, Wilson RI, Schnell E, Zang K, Wang
D, Nicoll RA, Lu B, Reichardt LF. 2000. The role of brain-derived
neurotrophic factor receptors in the mature hippocampus: modulation
of long-term potentiation through a presynaptic mechanism involving
TrkB. J Neurosci 20:6888–6897.
Yacoubian TA, Lo DC. 2000. Truncated and full-length TrkB receptors
regulate distinct modes of dendritic growth. Nat Neurosci 3:342–349.
Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV,
Bramham CR. 2002. Brain-derived neurotrophic factor induces long-
term potentiation in intact adult hippocampus: requirement for ERK
activation coupled to CREB and upregulation of Arc synthesis. J Neu-
rosci 22:1532–1540.
844 Pereira et al.
Journal of Neuroscience Research DOI 10.1002/jnr
